A federal judge has determined that the State of Kansas can move forward with its consumer protection lawsuit against Pfizer in state court, rejecting the pharmaceutical company’s attempt to transfer the case to federal jurisdiction under the Public Readiness and Emergency Preparedness (PREP) Act. This ruling is seen as a potentially significant development in the broader effort to hold vaccine manufacturers accountable for their public communications about COVID-19 vaccines.
U.S. District Judge Daniel D. Crabtree concluded that the claims brought by Kansas fall outside the protections of the PREP Act, which grants legal immunity to vaccine manufacturers for injury claims related to federally recommended pandemic countermeasures. Judge Crabtree emphasized that Kansas’ lawsuit focuses on allegations of deceptive marketing practices rather than claims of physical injury, and thus is not preempted by the Act. He stated, “That point alone ends the debate,” and ordered that the case be returned to the District Court of Thomas County, where it was originally filed.
The lawsuit, initiated by Kansas Attorney General Kris Kobach on June 17, 2024, accuses Pfizer of violating the Kansas Consumer Protection Act. The state alleges that Pfizer misrepresented its COVID-19 vaccine as “safe and effective,” while concealing evidence of serious risks and a decline in effectiveness over time. The complaint asserts that Pfizer failed to disclose potential links between the vaccine and conditions such as myocarditis, pericarditis, pregnancy complications, and deaths. Furthermore, it alleges that Pfizer falsely promoted the vaccine’s continued efficacy even as internal data indicated its effectiveness was waning, and misled the public by claiming the vaccine would prevent transmission of the virus, despite not conducting studies to support that claim.
It is important to note that the Kansas case does not involve claims of injury or wrongful death. Instead, it centers on the argument that Pfizer’s public communications misled consumers and violated state law.
Pfizer initially managed to have the lawsuit moved to federal court in July 2024, arguing that the PREP Act completely preempted Kansas’ claims. In October, the company reiterated its position, asserting that federal law invalidated the state’s consumer protection claims under federal preemption doctrines. However, Judge Crabtree dismissed this argument, clarifying that the PREP Act’s protections do not extend to claims based solely on marketing conduct rather than physical injuries. He wrote, “This case is about deceptive representations made to consumers — not about physical injuries from vaccine administration”.
Legal experts believe this ruling could have a substantial impact on how vaccine-related litigation proceeds across the country. Ray Flores, senior outside counsel for Children’s Health Defense (CHD), described the decision as a “first-of-its-kind ruling” that denies Pfizer blanket immunity for alleged deceptive practices. He suggested that the ruling creates a viable path for Pfizer to potentially be held accountable for its actions on a large scale. CHD General Counsel Kim Mack Rosenberg noted that the decision might encourage other states to pursue legal actions under their own consumer protection laws.
Historically, most courts have upheld Pfizer’s immunity under the PREP Act. For example, a similar lawsuit filed by the State of Texas was dismissed by a federal court in the Northern District of Texas. Flores highlighted that the Kansas decision “sets a new, persuasive precedent and provides a roadmap for others to follow”.
Other legal challenges to the PREP Act’s protections are ongoing in various states. In North Carolina, the state Supreme Court ruled that the PREP Act does not override state laws requiring parental consent for medical treatment, allowing a case involving a minor vaccinated without parental consent to proceed. Additionally, a federal court ruled in November 2024 that the PREP Act does not shield vaccine manufacturers from breach-of-contract claims, as seen in a case involving AstraZeneca and a participant in its vaccine trial.
Pfizer is expected to appeal Judge Crabtree’s decision. If the ruling is upheld, the company will face a public trial in Kansas state court and will be required to defend its vaccine marketing practices in detail. Legal observers suggest that this decision could represent a turning point in vaccine-related litigation, particularly for cases focused on allegedly misleading public communications rather than physical harm. Whether other states will follow Kansas’ example remains uncertain, but the ruling indicates that some courts may be willing to scrutinize the actions of vaccine manufacturers outside the scope of federal liability protections, especially when those actions pertain to public messaging rather than medical injury.
Sources:
